Investing.com - Ginkgo Bioworks (NYSE: DNA) reported first quarter EPS of $-0.100, $0.11 better than the analyst estimate of $-0.208. Revenue for the quarter came in at $98.29M versus the consensus estimate of $88.64M.
Ginkgo Bioworks's stock price closed at $1.400. It is down -29.650% in the last 3 months and down -67.060% in the last 12 months.
Ginkgo Bioworks saw 0 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See Ginkgo Bioworks's stock price’s past reactions to earnings here.
According to InvestingPro, Ginkgo Bioworks's Financial Health score is "weak performance".
Check out Ginkgo Bioworks's recent earnings performance, and Ginkgo Bioworks's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar